Trials / Completed
CompletedNCT00373568
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
Miltefosine (42 Days) for Mucosal Leishmaniasisi
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (planned)
- Sponsor
- AB Foundation · Academic / Other
- Sex
- All
- Age
- 12 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis
Detailed description
Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | miltefosine: 2.5 mg/kg/day for 42 days |
Timeline
- Start date
- 2005-04-01
- Completion
- 2007-12-01
- First posted
- 2006-09-08
- Last updated
- 2010-06-02
Locations
1 site across 1 country: Bolivia
Source: ClinicalTrials.gov record NCT00373568. Inclusion in this directory is not an endorsement.